The investigational HIF-2α inhibitor casdatifan demonstrated antitumor activity as monotherapy and in combination regimens across the ARC-20 platform study.
|Videos|September 25, 2020
Gender disparity seen with renal cell carcinoma management
Author(s)Urology Times staff
Meredith R. Metcalf, MD, discusses recent research evaluating management of clinical T1a RCC in men and women.
Advertisement
In this interview, Meredith R. Metcalf, MD, discusses a paper published in Urology titled "Gender Differences in the Clinical Management of Renal Cell Carcinoma," for which she served as a study author. Metcalf is instructor of urology at Johns Hopkins University, Baltimore.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Urology Times
1
Darolutamide associated with less cognitive change than enzalutamide in prostate cancer
2
ESMO 2026: Key presentations across genitourinary oncology
3
How PSMA-PET shapes staging and recurrence workup in prostate cancer
4
Gedatolisib plus darolutamide shows preliminary activity in mCRPC
5